

# Risks of myocarditis, pericarditis, and cardiac arrhythmia after vaccination or SARS-CoV-2 infection

Nature Medicine

28, 410-422

DOI: [10.1038/s41591-021-01630-0](https://doi.org/10.1038/s41591-021-01630-0)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. <i>Metabolism Open</i> , 2022, 13, 100159.	1.4	30
3	COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports. <i>Cureus</i> , 2022, 14, e21740.	0.2	9
4	A comparative safety study of reported neurological adverse events with three COVID-19 vaccines. <i>Journal of Neurology</i> , 2022, 269, 2301-2303.	1.8	3
5	COVID-19 Pathogenesis and Clinical Manifestations. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 231-249.	1.9	21
7	The Coronavirus pandemic “ 2022: Viruses, variants & vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 1-9.	3.2	31
9	A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, e104.	1.1	2
10	Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and Scotland. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
11	Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?. <i>Vaccines</i> , 2022, 10, 308.	2.1	21
12	The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data. <i>Vaccines</i> , 2022, 10, 320.	2.1	19
13	Postvaccine Myocarditis: A Risk Worth the Reward?. <i>Radiology</i> , 2022, 304, 563-565.	3.6	1
14	Case Report: Myocarditis After COVID-19 Vaccination “ Case Series and Literature Review. <i>Frontiers in Medicine</i> , 2022, 9, 836620.	1.2	7
17	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
18	Myocarditis Following the Second Dose of COVID-19 Vaccination in a Japanese Adolescent. <i>Cureus</i> , 2022, 14, e23474.	0.2	2
19	The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis. <i>Netherlands Heart Journal</i> , 2022, 30, 190-197.	0.3	5
20	Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination. <i>Open Heart</i> , 2022, 9, e001957.	0.9	19
22	An Interesting Case of Fatal Myasthenic Crisis Probably Induced by the COVID-19 Vaccine. <i>Cureus</i> , 2022, 14, e23251.	0.2	8
23	2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1717-1756.	1.2	220
24	COVID-19 vaccination: The road ahead. <i>Science</i> , 2022, 375, 1127-1132.	6.0	134

#	ARTICLE	IF	CITATIONS
25	Mechanical Circulatory Support in COVID-19. <i>Cardiology Clinics</i> , 2022, , .	0.9	3
26	Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. <i>Frontiers in Medicine</i> , 2022, 9, 838564.	1.2	24
28	COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates. <i>World Journal for Pediatric &amp; Congenital Heart Surgery</i> , 2022, , 215013512210859.	0.3	1
29	Adverse events following vaccination against coronavirus disease 2019. <i>Kosin Medical Journal</i> , 2022, 37, 18-26.	0.1	0
30	Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. <i>Emerging Microbes and Infections</i> , 2022, 11, 885-893.	3.0	39
31	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 40-51.	0.5	14
32	Case Series of Three Neurological Side Effects in Younger-Aged Individuals After Pfizer's mRNA Vaccine. <i>Cureus</i> , 2022, 14, e23779.	0.2	0
33	Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination â€” PCORnet, United States, January 2021â€”January 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 517-523.	9.0	95
34	Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination: A Pragmatic Narrative Review to Guide Clinical Practice. <i>Heart Lung and Circulation</i> , 2022, 31, 924-933.	0.2	6
35	Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 173-182.	1.5	13
36	Implications of COVID-19 Vaccination on Hospital Encounters and Outcomes. <i>American Journal of Cardiology</i> , 2022, 170, 105-111.	0.7	3
37	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
38	A rare case of COVID-19 vaccine-induced myopericarditis in a young adult. <i>Radiology Case Reports</i> , 2022, 17, 1916-1920.	0.2	5
39	A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab663.	0.4	4
40	Now is the time to consider measures against next wave of COVID-19. <i>Osong Public Health and Research Perspectives</i> , 2021, 12, 343-345.	0.7	0
41	Riskâ€”benefit analysis of COVID-19 vaccines â€” a neurological perspective. <i>Nature Reviews Neurology</i> , 2022, 18, 69-70.	4.9	6
44	To aspirate or not to aspirate? Considerations for the COVID-19 vaccines. <i>Pharmacological Reports</i> , 2022, 74, 1223-1227.	1.5	6
46	SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. <i>JAMA Cardiology</i> , 2022, 7, 600.	3.0	115

#	ARTICLE	IF	CITATIONS
47	Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach. <i>International Journal of Cardiology</i> , 2022, 358, 136-139.	0.8	9
48	Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction. <i>Journal of Infection</i> , 2022, 85, e21-e23.	1.7	5
49	Intermittent complete heart block with ventricular standstill after Pfizer COVID-19 booster vaccination: A case report. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12723.	0.4	3
50	Estimating the US pericarditis prevalence using national health encounter surveillance databases. <i>Current Medical Research and Opinion</i> , 2022, , 1-5.	0.9	0
51	Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19. <i>Experimental Biology and Medicine</i> , 2022, 247, 1205-1213.	1.1	14
52	The Cardiovascular Manifestations of COVID-19. <i>Cardiology Clinics</i> , 2022, 40, 277-285.	0.9	5
53	Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines. <i>Pharmaceuticals</i> , 2022, 15, 525.	1.7	6
54	COVID-19 Vaccination-Induced Cardiomyopathy Requiring Permanent Left Ventricular Assist Device. <i>Cureus</i> , 2022, , .	0.2	1
55	Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave. <i>Scientific Reports</i> , 2022, 12, 6978.	1.6	27
56	CMR findings after COVID-19 and after COVID-19-vaccination" same but different?. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 2057-2071.	0.2	3
57	Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data. <i>Vaccines</i> , 2022, 10, 744.	2.1	11
58	Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations. <i>Vaccines</i> , 2022, 10, 722.	2.1	11
59	Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician. <i>Current Atherosclerosis Reports</i> , 2022, 24, 563-570.	2.0	35
60	Myocarditis Following COVID-19 Vaccination. <i>Cardiology Clinics</i> , 2022, 40, 375-388.	0.9	10
61	Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5 to 11 Years. <i>Pediatrics</i> , 2022, 150, .	1.0	8
63	Possible Correlations between the COVID-19 mRNA Vaccine and Contracting Myocarditis/Pericarditis in Young Adults. <i>Journal of Biomedical Research &amp; Environmental Sciences</i> , 2022, 3, 453-456.	0.1	0
64	Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022. <i>Current Cardiology Reports</i> , 0, , .	1.3	2
65	Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. <i>Vaccine</i> , 2022, 40, 4663-4671.	1.7	25

#	ARTICLE	IF	CITATIONS
66	Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical Trial. SSRN Electronic Journal, 0, , .	0.4	1
68	Impairment of the Cardiovascular System during SARS-CoV-2 Infection. , 0, , .		0
69	COVID-19 Pandemic-Revealed Consistencies and Inconsistencies in Healthcare: A Medical and Organizational View. Healthcare (Switzerland), 2022, 10, 1018.	1.0	10
70	Vaccine mandates for healthcare workers beyond COVID-19. Journal of Medical Ethics, 2023, 49, 211-220.	1.0	18
71	Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open, 2022, 12, e059223.	0.8	34
72	Sex Differences in Clinical Characteristics, Management Strategies, and Outcomes of STEMI With COVID-19: NACMI Registry. , 2022, , 100360.		3
73	Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. Vaccine, 2022, 40, 4394-4402.	1.7	22
74	Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102513.	1.8	18
75	Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic. Frontiers in Immunology, 0, 13, .	2.2	8
76	The benefits of COVID-19 vaccination programmes for children may not outweigh the risks. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 1843-1845.	0.7	7
77	Myocardial Injury and Altered Gene Expression Associated with SARS-CoV-2 Infection or mRNA Vaccination. SSRN Electronic Journal, 0, , .	0.4	0
78	Acute Pericarditis: Update. Current Cardiology Reports, 2022, 24, 905-913.	1.3	14
79	Frequency of Neurological Diseases After COVID-19, Influenza A/B and Bacterial Pneumonia. Frontiers in Neurology, 0, 13, .	1.1	29
80	Cardiac Complications of COVID-19 in Low-Risk Patients. Viruses, 2022, 14, 1322.	1.5	9
81	Multiple attacks of transient monocular visual loss in a previously healthy man: a possible complication after COVID-19 vaccination?. International Journal of Retina and Vitreous, 2022, 8, .	0.9	3
82	COVID-19 vaccination and cardiac dysfunction. World Journal of Cardiology, 2022, 14, 343-354.	0.5	3
83	Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet, The, 2022, 399, 2191-2199.	6.3	108
84	Long-term cardiac surveillance and outcomes of COVID-19 patients. Trends in Cardiovascular Medicine, 2022, 32, 465-475.	2.3	6

#	ARTICLE	IF	CITATIONS
85	Placing the risk of myopericarditis following COVID-19 vaccination into perspective. <i>European Heart Journal</i> , 0, , .	1.0	0
86	Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services. <i>Clinical Infectious Diseases</i> , 2022, 75, S11-S17.	2.9	8
87	Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
88	COVID-19 mRNA vaccination and myocarditis or pericarditis. <i>Lancet, The</i> , 2022, 399, 2168-2169.	6.3	22
89	Mammographic findings of diffuse axillary tail trabecular thickening following immunization with mRNA COVID-19 vaccines: Case series study. <i>Radiology Case Reports</i> , 2022, 17, 2841-2849.	0.2	1
90	Adult-Onset Still's Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature. <i>Vaccines</i> , 2022, 10, 1022.	2.1	6
91	Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects. <i>Pathogens</i> , 2022, 11, 743.	1.2	11
92	Adverse Reactions of COVID-19 Vaccines. <i>Journal of Clinical Otolaryngology</i> , 2022, 33, 92-104.	0.1	1
93	Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. <i>Nature Communications</i> , 2022, 13, .	5.8	60
94	Atrial fibrillation after vaccination for COVID-19: analysis of the vaccine adverse event reporting system. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 1-2.	0.6	9
95	Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns. <i>Diagnostics</i> , 2022, 12, 1555.	1.3	22
96	Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. <i>Viruses</i> , 2022, 14, 1415.	1.5	39
97	<sc>RNA</sc> therapeutics in the clinic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	31
98	Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?. <i>Journal of Cardiac Failure</i> , 2023, 29, 108-111.	0.7	4
99	Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. <i>Vaccine</i> , 2022, 40, 5153-5159.	1.7	33
100	Myocardial injury after COVID-19 infection and vaccination. Two sides of the same coin or different?. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 2073-2075.	0.2	0
101	Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies. <i>Vaccines</i> , 2022, 10, 1067.	2.1	8
102	Cardiovascular symptom phenotypes of post-acute sequelae of SARS-CoV-2. <i>International Journal of Cardiology</i> , 2022, 366, 35-41.	0.8	9

#	ARTICLE	IF	CITATIONS
103	Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. <i>BMJ</i> , The, 0, , e069445.	3.0	64
104	Risk of Cardiovascular Events After COVID-19. <i>American Journal of Cardiology</i> , 2022, 179, 102-109.	0.7	19
105	Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
106	Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. <i>BMJ Open</i> , 2022, 12, e060425.	0.8	9
107	A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
108	COVID-19 Vaccine-Related Arthritis: A Descriptive Study of Case Reports on a Rare Complication. <i>Cureus</i> , 2022, , .	0.2	2
109	Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout. <i>Frontiers in Drug Delivery</i> , 0, 2, .	0.4	1
110	mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	31
111	COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 1161-1173.	1.5	16
112	Differences in Treating Patients with Palpitations at the Primary Healthcare Level Using Telemedical Device Savvy before and during the COVID-19 Pandemic. <i>Micromachines</i> , 2022, 13, 1176.	1.4	1
113	(Epi)transcriptomics in cardiovascular and neurological complications of COVID-19. , 2022, 1, 100013.		4
114	Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. <i>PLoS Medicine</i> , 2022, 19, e1004056.	3.9	27
115	COVID-19 Vaccines and Myopericarditis: A Nuanced Story. <i>Journal of Personalized Medicine</i> , 2022, 12, 1242.	1.1	0
116	Macro-troponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection. <i>Clinical Chemistry</i> , 2022, 68, 1015-1019.	1.5	8
118	Four cases of cytokine storm after COVID-19 vaccination: Case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
119	Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020-2022. <i>Vaccines</i> , 2022, 10, 1317.	2.1	2
120	Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. <i>Circulation</i> , 2022, 146, 743-754.	1.6	107
121	Catecholamines Are the Key Trigger of COVID-19 mRNA Vaccine-Induced Myocarditis: A Compelling Hypothesis Supported by Epidemiological, Anatomopathological, Molecular, and Physiological Findings. <i>Cureus</i> , 2022, , .	0.2	7

#	ARTICLE	IF	CITATIONS
122	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1577-1586.	4.6	32
123	Vaccines and Heart Failure: Analysis of Vaccine Adverse Event Reporting System Between 1990 and 2021. <i>American Journal of Therapeutics</i> , 0, Publish Ahead of Print, .	0.5	0
124	Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
128	COVID-19-Induced Myocarditis and mRNA Vaccine-Related Pericarditis: A Case Report. <i>Cureus</i> , 2022, , .	0.2	1
129	Genetic basis of sudden death after COVID-19 vaccination in Thailand. <i>Heart Rhythm</i> , 2022, 19, 1874-1879.	0.3	10
130	Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study. <i>Vaccine</i> , 2022, 40, 5709-5715.	1.7	4
131	Vaccination nudges: A study of pre-booked COVID-19 vaccinations in Sweden. <i>Social Science and Medicine</i> , 2022, 309, 115248.	1.8	9
133	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 29, 100586.	1.3	6
134	Vaccine-associated myocarditis: a case report and summary of the literature. <i>World Journal of Emergency Medicine</i> , 2022, 13, .	0.5	1
135	COVID-19 Vaccination-Induced Ventricular Fibrillation in an Afebrile Patient With Brugada Syndrome. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	4
136	COVID-19 and Myocarditis: Review of Clinical Presentations, Pathogenesis and Management. <i>Heart International</i> , 2022, 16, 20.	0.4	10
137	Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	53
138	Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic. <i>World Journal of Clinical Cases</i> , 2022, 10, 9556-9572.	0.3	9
139	COVID-19 and the heart. <i>British Medical Bulletin</i> , 2022, 144, 4-11.	2.7	5
140	Cardiac Safety of mRNA-Based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis. <i>Pathogens</i> , 2022, 11, 1001.	1.2	2
141	A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis. <i>American Journal of Preventive Medicine</i> , 2023, 64, 275-284.	1.6	18
142	Complex Management Decisions in a Professional Athlete With Recurrent Pericarditis. <i>JACC: Case Reports</i> , 2022, 4, 1090-1093.	0.3	1
143	Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10881.	1.8	23



#	ARTICLE	IF	CITATIONS
144	Incessant pericarditis following the second dose of SARS-CoV-2 mRNA vaccine successfully treated with anakinra: a case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.3	1
145	Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine - Part 1. <i>Journal of Insulin Resistance</i> , 2022, 5, .	0.6	8
146	Retrospective record review on timing of COVID-19 vaccination and cardiac surgery. <i>Journal of Cardiac Surgery</i> , 2022, 37, 3634-3638.	0.3	5
147	Chronological Development of Cardiovascular Disease in Times of COVID-19: A Retrospective Analysis of Hospitalized Diseases of the Circulatory System and COVID-19 Patients of a German University Hospital. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 325.	0.8	2
148	Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
149	Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. <i>European Journal of Heart Failure</i> , 2022, 24, 2000-2010.	2.9	58
150	An autopsy case report of aortic dissection complicated with histiolymphocytic pericarditis and aortic inflammation after mRNA COVID-19 vaccination. <i>Legal Medicine</i> , 2022, 59, 102154.	0.6	4
151	BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12-17 years in Scotland. <i>Lancet Regional Health - Europe, The</i> , 2022, 23, 100513.	3.0	8
152	Third-degree atrioventricular block associated with the SARS-CoV-2 mRNA vaccine. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2022, .	0.4	0
153	Myocarditis associated with COVID-19 and its vaccines - a systematic review. <i>Progress in Cardiovascular Diseases</i> , 2022, 74, 111-121.	1.6	11
154	IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination. <i>European Journal of Immunology</i> , 2022, 52, 1972-1979.	1.6	4
155	Myocardial Injury and Altered Gene Expression Associated With SARS-CoV-2 Infection or mRNA Vaccination. <i>JACC Basic To Translational Science</i> , 2023, 8, 124-137.	1.9	12
157	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	2.1	10
158	Safety, tolerability and immunogenicity of Biological Eâ€™s CORBEVAXâ€™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. <i>Vaccine</i> , 2022, 40, 7130-7140.	1.7	17
159	Features and follow-up of patients affected by noninflammatory myocarditis after coronavirus disease 2019 vaccination. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, 65-68.	0.6	3
160	Year 3 of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2324-2332.	1.4	3
161	Arrhythmias after SARS-CoV-2 Vaccination in Patients with a Cardiac Implantable Electronic Device: A Multicenter Study. <i>Biomedicines</i> , 2022, 10, 2838.	1.4	7
162	Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1900-1908.	1.2	16

#	ARTICLE	IF	CITATIONS
163	Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
164	mRNA COVID-19 vaccines are well tolerated and myopericarditis is a rare adverse event following immunisation. <i>Drugs and Therapy Perspectives</i> , 2022, 38, 532-540.	0.3	3
165	Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. <i>Expert Review of Vaccines</i> , 2023, 22, 1-16.	2.0	21
166	Associations between COVID-19 and hospitalisation with respiratory and non-respiratory conditions: a record linkage study. <i>Medical Journal of Australia</i> , 2023, 218, 33-39.	0.8	2
167	Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
168	Pathogenesis and Preventive Tactics of Immune-Mediated Non-Pulmonary COVID-19 in Children and Beyond. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14157.	1.8	3
169	Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12-17-year olds in Victoria, Australia. <i>BMJ Paediatrics Open</i> , 2022, 6, e001472.	0.6	8
170	Post COVID, Ergo Propter COVID?. <i>JACC: Case Reports</i> , 2023, 6, 101706.	0.3	0
171	Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia. <i>Vaccines</i> , 2022, 10, 1981.	2.1	3
172	Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
173	Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 0, , 1-10.	2.0	6
175	COVID-19 and NSTEMI Outcomes among Hospitalized Patients in the United States and Racial Disparities in Mortality: Insight from National Inpatient Sample Database. <i>Vaccines</i> , 2022, 10, 2024.	2.1	3
176	Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. <i>Cmaj</i> , 2022, 194, E1529-E1536.	0.9	20
177	COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review. <i>Vaccines</i> , 2022, 10, 2039.	2.1	2
178	SARS-CoV-2 Infection and COVID-19 in Children. <i>Clinics in Chest Medicine</i> , 2023, 44, 359-371.	0.8	6
179	COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation. <i>Current Cardiology Reports</i> , 2022, 24, 2031-2041.	1.3	9
181	mRNA therapy for myocardial infarction: A review of targets and delivery vehicles. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
183	Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis. <i>Journal of the American College of Cardiology</i> , 2022, 80, 2255-2265.	1.2	27

#	ARTICLE	IF	CITATIONS
185	Impaired VEGF-A-Mediated Neurovascular Crosstalk Induced by SARS-CoV-2 Spike Protein: A Potential Hypothesis Explaining Long COVID-19 Symptoms and COVID-19 Vaccine Side Effects?. <i>Microorganisms</i> , 2022, 10, 2452.	1.6	8
186	Management of cardiovascular symptoms after Pfizer-BioNTech COVID-19 vaccine in teenagers in the emergency department. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 699-706.	0.8	3
187	The impact of COVID-19 on the cardiovascular health of emerging adults aged 18-25: findings from a scoping review. , 2022, , .		0
189	Coronavirus Disease-2019 Vaccine Hesitancy. <i>Pediatric Clinics of North America</i> , 2023, 70, 243-257.	0.9	2
191	Willingness of Brazilian caregivers in having their children and adolescents vaccinated against Covid-19. <i>Vaccine</i> , 2023, 41, 735-743.	1.7	6
192	Current evidence of COVID-19 vaccination-related cardiovascular events. <i>Postgraduate Medicine</i> , 2023, 135, 102-120.	0.9	5
193	Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to <sc>SARSâ€CoV</sc>â€2 <sc>mRNA</sc>â€1237 vaccine in patients with solid tumors. <i>Molecular Oncology</i> , 2023, 17, 686-694.	2.1	1
194	COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. <i>Hypertension Research</i> , 2023, 46, 589-600.	1.5	14
195	COVID-19 Associated Myocarditis Clinical Outcomes among Hospitalized Patients in the United States: A Propensity Matched Analysis of National Inpatient Sample. <i>Viruses</i> , 2022, 14, 2791.	1.5	10
196	Myopericarditis following both BNT162b2 and NVX-CoV2373. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, .	0.9	5
197	Recent highlights on myocarditis, cardiovascular complications of COVID-19, and cardiomyopathies from the International Journal of Cardiology: Heart & Vasculature. <i>IJC Heart and Vasculature</i> , 2022, 43, 101154.	0.6	0
198	Cardiac assessment of patients during post COVID-19 recovery phase: a prospective observational study. <i>Global Cardiology Science &amp; Practice</i> , 2022, 2022, .	0.3	0
199	Antiviral Approaches against Influenza Virus. <i>Clinical Microbiology Reviews</i> , 2023, 36, .	5.7	18
200	Risks of Cardiac Arrhythmia Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2023, 11, 112.	2.1	3
201	<sc>COVID</sc>â€19 vaccine induced myocarditis in young males: Aâsystematic review. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	11
203	Changes of ECG parameters after BNT162b2 vaccine in the senior high school students. <i>European Journal of Pediatrics</i> , 2023, 182, 1155-1162.	1.3	12
204	The Incidence of Myocarditis Following an Influenza Vaccination: A Population-Based Observational Study. <i>Drugs and Aging</i> , 0, , .	1.3	1
205	Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study. <i>Anesthesia and Pain Medicine</i> , 0, , .	0.5	2

#	ARTICLE	IF	CITATIONS
206	Impact of COVID-19 on Patients Hospitalized with ST-Segment Elevation Myocardial Infarction in the United States during the Early Pandemic: An Analysis of Outcomes, Care Delivery, and Racial Disparities in Mortality. <i>Infectious Disease Reports</i> , 2023, 15, 55-65.	1.5	8
207	Acute myocarditis after a first dose of COVID-19 mRNA vaccination: an uncommon but potentially serious adverse effect. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, 154-158.	0.6	1
208	Electrocardiographic Pathological Findings Caused by the SARS-CoV-2 Virus Infection: Evidence from a Retrospective Multicenter International Cohort Longitudinal Pilot Study of 548 Subjects. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 58.	0.8	1
209	10-year survival outcome after clinically suspected acute myocarditis in adults: A nationwide study in the pre-COVID-19 era. <i>PLoS ONE</i> , 2023, 18, e0281296.	1.1	2
210	Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging. <i>Cureus</i> , 2023, , .	0.2	0
211	COVID-19 Associated Fulminant Myocarditis in a Fully-Vaccinated Female: A Case Report with Clinical Follow-up. <i>Clinical Medicine Insights: Case Reports</i> , 2023, 16, 117954762211472.	0.3	3
213	Status of and perspectives on COVID-19 vaccination after lifting of the dynamic zero-COVID policy in China. <i>Global Health &amp; Medicine</i> , 2023, 5, 112-117.	0.6	4
214	Impact of COVID-19 vaccination in post-COVID cardiac complications. <i>Vaccine</i> , 2023, , .	1.7	2
215	Cardiac Arrhythmias in Post-COVID Syndrome: Prevalence, Pathology, Diagnosis, and Treatment. <i>Viruses</i> , 2023, 15, 389.	1.5	17
216	Real-Time Classification of Cardiac Events in Arrhythmia Disease. , 2022, , .		0
217	Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
218	Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada. <i>JAMA Pediatrics</i> , 2023, 177, 410.	3.3	3
219	Superior possibilities and upcoming horizons for nanoscience in COVID-19: noteworthy approach for effective diagnostics and management of SARS-CoV-2 outbreak. <i>Chemical Papers</i> , 2023, 77, 4107-4130.	1.0	3
220	Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. , 2023, 2, e000373.		14
221	Cardiovascular Manifestations of Long COVID. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
222	Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population. <i>Pathogens</i> , 2023, 12, 233.	1.2	7
223	Pediatric Pericarditis: Update. <i>Current Cardiology Reports</i> , 0, , .	1.3	3
224	Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2023, 59, 173-180.	0.8	9

#	ARTICLE	IF	CITATIONS
225	How to use COVID-19 antiviral drugs in patients with chronic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
226	Atrial Fibrillation After mRNA-1273 SARS-CoV-2 Vaccination: Case Report with Literature Review. <i>Risk Management and Healthcare Policy</i> , 0, Volume 16, 209-214.	1.2	5
227	Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508.	1.5	15
228	Public Choice Theory: An Explanation of the Pandemic Policy Responses. <i>Studies in Public Choice</i> , 2023, , 97-132.	0.0	1
229	The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. <i>European Heart Journal Supplements</i> , 2023, 25, A42-A49.	0.0	10
230	Cox regression using a calendar time scale was unbiased in simulations of COVID-19 vaccine effectiveness & safety. <i>Journal of Clinical Epidemiology</i> , 2023, 156, 127-136.	2.4	8
231	Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines. <i>Circulation</i> , 2023, 147, 877-880.	1.6	8
232	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	3.3	4
233	Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase. <i>Drugs - Real World Outcomes</i> , 2023, 10, 263-270.	0.7	3
235	Effectiveness and safety of coronavirus disease 2019 vaccines. <i>Current Opinion in Pulmonary Medicine</i> , 2023, 29, 138-142.	1.2	1
236	The Cardiovascular Manifestations of COVID-19. <i>Heart Failure Clinics</i> , 2023, 19, 153-161.	1.0	3
237	Myocarditis Following COVID-19 Vaccination. <i>Heart Failure Clinics</i> , 2023, 19, 251-264.	1.0	4
238	Mechanical Circulatory Support in COVID-19. <i>Heart Failure Clinics</i> , 2023, 19, 205-211.	1.0	0
239	Response by Mills et al Regarding Article, "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex". <i>Circulation</i> , 2023, 147, .	1.6	6
240	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5011.	1.8	1
241	Incidence and risk factors of myocarditis in hospitalized patients with COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
242	Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2023, 76, 555-563.	0.4	1
243	COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5374.	1.8	6

#	ARTICLE	IF	CITATIONS
244	Natural Course of COVID-19 and Independent Predictors of Mortality. <i>Biomedicines</i> , 2023, 11, 939.	1.4	5
245	Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysis. <i>The Lancet Digital Health</i> , 2023, 5, e206-e216.	5.9	1
246	COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations. , 2023, 14, 2071.		4
247	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944.	1.8	12
248	Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2023, 61, 47-61.	0.2	4
249	Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a caseâ€“control study. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 35, 100745.	1.3	2
250	Short term outcome of myocarditis and pericarditis following COVID-19 vaccines:Âa cardiac magnetic resonance imaging study. <i>International Journal of Cardiovascular Imaging</i> , 0, , .	0.7	2
251	Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis. <i>American Journal of Health, Medicine and Nursing Practice</i> , 2023, 8, 10-18.	0.1	0
252	Cardiovascular magnetic resonance for evaluation of cardiac involvement in COVID-19: recommendations by the Society for Cardiovascular Magnetic Resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2023, 25, .	1.6	14
253	Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand. <i>Vaccines</i> , 2023, 11, 749.	2.1	5
254	COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events. <i>Vaccines</i> , 2023, 11, 747.	2.1	9
255	Immunopathogenesis and immunomodulatory therapy for myocarditis. <i>Science China Life Sciences</i> , 2023, 66, 2112-2137.	2.3	5
256	Evidence-based policies in public health to address COVID-19 vaccine hesitancy. <i>Future Virology</i> , 2023, 18, 261-273.	0.9	5
257	Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. <i>EClinicalMedicine</i> , 2023, 58, 101932.	3.2	4
259	Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia. <i>Vaccine: X</i> , 2023, 14, 100303.	0.9	1
260	Case report: mRNA-1273 COVID-19 vaccine-associated myopericarditis: Successful treatment and re-exposure with colchicine. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
271	Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination. <i>Npj Vaccines</i> , 2023, 8, .	2.9	4
294	The Potential Role of Medicinal Plants, Traditional Herbal Medicines, and Formulations to Overcome SARS-CoV-2 Induced Health Crisis. <i>Sustainable Development and Biodiversity</i> , 2023, , 465-524.	1.4	0

#	ARTICLE	IF	CITATIONS
309	Susceptibility of SARS-CoV2 infection in children. European Journal of Pediatrics, 2023, 182, 4851-4857.	1.3	1
330	Side effects of vaccines. Side Effects of Drugs Annual, 2023, , .	0.6	0
350	Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology, 2024, 22, 75-88.	13.6	1
357	Present situation about COVID-19 patients with myocarditis: how to protect the at-risk crowd. , 2024, , .		0
369	SARS-CoV-2, COVID-19, and Children: Myths and Evidence. , 2023, , 503-520.		0
376	Risk of carditis among adolescents after extending the interdose intervals of BNT162b2. Npj Vaccines, 2024, 9, .	2.9	0